Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules

Exclusion Criteria

• •1. Dry bronchiectasis mainly characterized by hemoptysis;
• •2. Bronchiectasis caused by cystic fibrosis, allergic bronchopulmonary aspergillosis, etc;
• •3. Previous respiratory diseases other than bronchiectasis (such as bronchial asthma, lung cancer, active pulmonary tuberculosis, interstitial lung disease, pulmonary thromboembolism and severe pneumonia, etc.);
• •4. Combined with serious diseases of the heart, liver, kidneys, digestive system, blood system, etc., evaluated by the researcher, including but not limited to acute severe hepatitis, liver failure, liver cirrhosis, acute renal failure, acute myocardial infarction, heart failure, gastric perforation, gastrointestinal bleeding, gastric cancer, intestinal cancer, acute leukemia, acute aplastic anemia, etc., subject to the judgment of the researcher;
• •5. Abnormal liver function was found in the patient screening examination, with the following criteria: total bilirubin \> 1.5×ULN; ALT \> 3×ULN; AST \> 3×ULN;
• •6. Inability to swallow the research drug;
• •7. Known allergy to the test drug;
• •8. Participate in other clinical trials, use other research drugs or research devices within 30 days before randomization;
• •9. Women or men of childbearing age refused to use contraceptive measures during the study period;
• •10. Pregnant or lactating women;
• •11. Any other factors that may not be suitable for participation in clinical research as determined by the researcher;
• •12. In the past year, there has been a history of alcohol abuse, drug abuse or drug abuse;
• •13. Other traditional Chinese medicine treatments were used within 7 days before the use of the study drug and during the study period.